Joseph P Vacanti, 5563 E Green St, Dunkirk, NY 14048

6348069, Feb 19, 2002

Nov 3, 1998

09/185360

Joseph P. Vacanti - Winchester MA
Christopher K. Breuer - Brighton MA
Beverly E. Chaignaud - Brookline MA

Childrens Medical Center Corporation - Boston MA

A61F 202

623 1111

It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.

6455311, Sep 24, 2002

Apr 28, 2000

09/560480

Joseph P. Vacanti - Winchester MA

The General Hospital Corporation - Boston MA

C12N 506

435395, 435 11, 435 12

Disclosed and claimed is a laminar structure. The laminar structure has multiple layers. Each layer has tissue and vasculature. The layers are abjacent. The vasculature is in three dimensions through the structure. The structure has connections for flow into and out of the vasculature. The structure can be implanted directly by connecting blood vessels to flow into and out of the vasculature.

6692738, Feb 17, 2004

Jan 26, 2001

09/770339

David T. MacLaughlin - Saugus MA
Joseph P. Vacanti - Winchester MA
Patricia K. Donahoe - Boston MA
Peter T. Masiakos - Boston MA

The General Hospital Corporation - Boston MA

A61K 4800

424 9321, 424484, 435455, 435325

Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptinâ, interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.

6840962, Jan 11, 2005

Sep 25, 2000

09/670051

Charles A. Vacanti - Lexington MA, US
Yi Lin Cao - Shrewsbury MA, US
Robert S. Langer - Newton MA, US
Joseph P. Vacanti - Winchester MA, US
Keith Paige - Brookline MA, US
Joseph Upton - Brookline MA, US

Massachusetts Institute of Technology - Cambridge MA
Children's Medical Center Corporation - Boston MA

A61F 202

623 2376, 623 1317

Connective tissue, including neo-tendons and ligaments, has been constructed using biodegradable synthetic scaffolds seeded with tenocytes. The scaffolds are preferably formed from biodegradable fibers formed of a polymer such as polyglycolic acid-polylactic acid copolymers, and seeded with cells isolated from autologous tendon or ligament by means of enzymatic digestion or direct seeding into tissue culture dishes from explants. The cell polymer constructs are then surgically transplanted to replace missing segments of functioning tendon or ligament.

6899915, May 31, 2005

Nov 29, 2001

09/997734

Pamela C. Yelick - Concord MA, US
John D. Bartlett - Acton MA, US
Joseph P. Vacanti - Winchester MA, US
Bjorn R. Olsen - Milton MA, US
Phillip Stashenko - Medfield MA, US

President and Fellows of Harvard College - Cambridge MA
General Hospital Corporation - Boston MA
Forsyth Dental Infirmary for Children, Inc. - Boston MA

A61C013/08

427 226, 4332021, 433204, 264 19, 523115

Tooth tissues include the pulp mesenchyme that forms the dentin and an epithelium that is responsible for enamel formation. Cells from these tissues were obtained from porcine third molars and were seeded onto a biodegradable scaffold composed of a polyglycolic acid—polylactic acid copolymer. Cell polymer constructs were then surgically implanted into the omentum of athymic nude rats so that the constructs would have a blood supply and these tissues were allowed to develop inside the rats. Infrequently, columnar epithelial cells were observed as a single layer on the outside of the dentin-like matrix similar to the actual arrangement of ameloblasts over dentin during early tooth development. Developing tooth tissues derived from such cell polymer constructs could eventually be surgically implanted into the gum of an edentulous recipient where the construct would receive a blood supply and develop to maturity, providing the recipient with a biological tooth replacement.

7078032, Jul 18, 2006

Oct 21, 2003

10/690077

David T. MacLaughlin - Saugus MA, US
Joseph P. Vacanti - Winchester MA, US
Patricia K. Donahoe - Boston MA, US
Peter T. Masiakos - Boston MA, US

The General Hospital Corporation - Boston MA

A61K 48/00
A61K 9/14
A01N 63/00
C12N 5/00
C12N 15/63
C12P 21/06
C12N 15/00

424 9321, 424 931, 424 932, 424484, 435 691, 4353201, 435325, 435455

Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin™, interferons, and anti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells.

7371400, May 13, 2008

Jan 2, 2002

10/038891

Jeffrey T. Borenstein - Cambridge MA, US
Kevin R. King - Cambridge MA, US
Hidetomi Terai - Osaka, JP
Joseph P. Vacanti - Boston MA, US

The General Hospital Corporation - Boston MA

A61F 2/00
C12N 11/02
C12N 11/08
C12N 5/06
C12N 5/08

424423, 435177, 435180, 435395

The invention provides for translating two-dimensional microfabrication technology into the third dimension. Two-dimensional templates are fabricated using high-resolution molding processes. These templates are then bonded to form three-dimensional scaffold structures with closed lumens. The scaffolds can serve as the template for cell adhesion and growth by cells that are added to the scaffolds through the vessels, holes or pores. These scaffolds can be formed by layering techniques, to interconnect flat template sheets to build up a fully vascularized organ.

7670797, Mar 2, 2010

Jul 15, 2005

11/183115

Joseph P. Vacanti - Boston MA, US
Robert Rubin - Brookline MA, US
Wing Cheung - Swampscott MA, US
Jeffrey T. Borenstein - Newton MA, US

The General Hospital Corporation - Boston MA
The Charles Stark Draper Laboratory - Cambridge MA

C12Q 1/24

435 30, 435 32, 435395

A method of determining toxicity of a test agent in a tissue including A) incubating a test agent within a three-dimensional tissue engineered structure comprising a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, and wherein the first mold or polymer scaffold has microchannels comprising vessels that bifurcate, and B) obtaining information from step A) to assess toxicity.